Rubius Therapeutics (NASDAQ:RUBY) stock is falling hard on Tuesday after the biotechnology company received a Nasdaq delisting notice. According to a filing with the U.S. Securities and Exchange ...
After several tireless days we have finished crunching the numbers from nearly 817 13F filings issued by the elite hedge funds and other investment firms that we track at Insider Monkey, which ...
Rubius Therapeutics, Inc., a biopharmaceutical company, focuses on the development of red cell therapeutics for the treatment of cancer and autoimmune diseases. The company was formerly known as VL26, ...
Investors in Rubius Therapeutics Inc (Symbol: RUBY) saw new options begin trading this week, for the June 18th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ...
Investors in Rubius Therapeutics Inc (Symbol: RUBY) saw new options become available this week, for the November 19th expiration. One of the key inputs that goes into the price an option buyer is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results